differing onset types have been classified as motion-triggered (MT) and non-motion-triggered (NMT) MdDS, respectively [3,4,5,11,12]. The MdDS clinical population demonstrates a female/male ratio of between 8:2 and 9:1 [4,5,8,10,13]. In females, the age of MdDS onset is commonly...
NMT reports research funding from BMS, Calithera Biosciences, Nektar Therapeutics, Exelixis, Pfizer, Novartis, Arrowhead Pharmaceuticals, Mirati Therapeutics, Takeda, Epizyme and Eisai Medical Research; consulting and advisory fees from BMS, Calithera Biosciences, Nektar Therapeutics, Exelixis, Pfizer, ...